Analysed ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) News Sources
Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming
14-04-2026
marketbeat.com
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
08-04-2026
yahoo.com
Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
27-03-2026
yahoo.com
Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
20-03-2026
yahoo.com
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
18-03-2026
yahoo.com
Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference
10-03-2026
marketbeat.com
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference
03-03-2026
yahoo.com
Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference
26-02-2026
marketbeat.com
What is the current price of ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)?
The current price of ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) is $4.17.
ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) absolute price change since previous trading day?
The absolute price change of ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) since the previous trading day is $-0.08.
ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) percentage price change since previous trading day?
The percentage price change of ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) since the previous trading day is -1.8824%.
What is the most recent average sentiment score for ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)?
The most recent average sentiment score for ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)?
The most recent sentiment for ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) is .
SEC-8K** Filing Available For ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.